Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677920 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL32677918 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL32677917 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL32677922 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL13531488 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL9369927 | 0.84 | CPB1 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL32677941 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AAGTR2ALDH1A1 | |
| SCHEMBL32677942 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AAGTR2ALDH1A1 | |
| SCHEMBL13888062 | 0.81 | HTR2C (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 | |
| SCHEMBL14720538 | 0.80 | PSEN1 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | HTR7, HTR3B, HTR3A | SMN1; SMN2 982/4885NPC1 227/4885RAB9A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.